EBioMedicine 64 (2021) 103226

Contents lists available at ScienceDirect

EBioMedicine

journal homepage: www.elsevier.com/locate/ebiom

Corrigendum

Corrigendum to "Circular RNA circPICALM sponges miR-1265 to inhibit bladder cancer metastasis and influence FAK phosphorylation" [EBioMedicine 48 (2019) 316–331]

Dong Yan[a,b,1], Wei Dong[a,b,1], Qingqing He[a,b,1], Meihua Yang[a,b], Lifang Huang[b], Jianqiu Kong[a,b], Haide Qin[a,b], Tianxin Lin[a,b,*], Jian Huang[a,b,*]

[a] *Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China*
[b] *Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, SunYat-sen Memorial Hospital, SunYat-sen University, Guangzhou, China*

The authors have recently noticed that the published version of this article contained errors in Fig. 4i and Fig. 7d. These inadvertent errors were made during figure preparation. The corrected Fig. 4 and Fig. 7 are presented below. These corrections do not change the description, interpretation, or the original conclusions of the manuscript. The authors apologize for any inconvenience caused by these unintentional errors.

DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2019.08.074.
* Corresponding authors.
E-mail addresses: lintx@mail.sysu.edu.cn (T. Lin), huangj8@mail.sysu.edu.cn (J. Huang).
[1] These authors contributed equally to this work.

https://doi.org/10.1016/j.ebiom.2021.103226



Fig. 4. circPICALM binds to and sponges miR-1265. a. RIP assay for circPICALM and PICALM mRNA fold changes in BC cells using anti-Ago2 or IgG antibodies. IgG was used as a negative control. b. Schematic illustration of the predicted binding sites between circPICALM and seven candidate miRNAs. c. and d. RNA pull-down assay with circPICALM or oligo probes, validated by gel electrophoresis and RT-PCR. e. Relative levels of seven candidate miRNAs in cell lysate pulled down by oligo or circPICALM probes were detected by RT-PCR. f. A dual-luciferase reporter assay in HEK-293T cells to prove the interaction between circPICALM and miR-1265. Wild-type or mutant circPICALM sequences were cloned into psi-CHECK-2 plasmids. Rluc intensity was normalized to firefly luciferase activity. g. Part of wild-type and mutant circPICALM sequences for the dual-luciferase reporter assay and the binding site for miR-1265. h. Biotin-labelled miR-1265 probe capture in circPICALM overexpression T24 and UM-UC-3 cells. The RNA abundance was measured by RT-PCR and normalized to input. i. Colocalization of miR-1265 and circPICALM in UM-UC-3 cells, demonstrated by FISH. Probe for miR-1265 was labelled by FAM and probe for circPICALM was labelled by cy3. Scale bar, 10 μm. (Data are presented as the mean ± SD, n = 3. Unpaired, two-tailed student's t test, $^{*}p<0.05$, $^{**}p<0.01$)



Fig. 7. STEAP4 decreases the pFAK/FAK ratio and influences EMT. a. Co-IP using anti-Flag antibody or IgG in wild-type BC cells or cells stably expressing STEAP4-3 × Flag. Proteins immunoprecipitated were detected by western blotting with anti-FAK and anti-Flag antibodies. b. and c. Western blotting showed FAK and its phosphorylation form in T24 and UM-UC-3 cells when silencing or overexpressing STEAP4. d. FAK Inhibitor 14 could eliminate the pro-metastasis effect of STEAP4 silencing, indicated by migration and Matrigel invasion assays. Scale bar, 100μm. e. Western blotting illustrated EMT markers expression in BC cells transfected with STEAP4 siRNAs. f. Model we propose that circPICALM sponges miR-1265 to influence the metastasis of BC. STEAP4 is a direct miR-1265 target and exerts its function on EMT through binding and inhibiting the phosphorylation of FAK. (Data are presented as the mean ± SD, n = 3. Unpaired, two-tailed student's *t* test, $^{*}p<0.05$, $^{**}p<0.01$)